{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T14:44:09Z","timestamp":1648565049139},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00393-018-0453-2","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T02:23:50Z","timestamp":1525400630000},"page":"290-296","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neue Antirheumatika"],"prefix":"10.1007","volume":"77","author":[{"given":"S.","family":"Throm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"H\u00f6mke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,4]]},"reference":[{"key":"453_CR1","volume-title":"Rheuma in Zahlen","year":"2018","unstructured":"Deutsche Gesellschaft f\u00fcr Rheumatologie (Hrsg) (2018) Rheuma in Zahlen. \n                    https:\/\/dgrh.de\/Start\/DGRh\/Presse\/Daten-und-Fakten\/Rheuma-in-Zahlen.html\n                    \n                  . Zugegriffen: 21. Jan. 2018"},{"key":"453_CR2","volume-title":"Anthony Cerami und David Wallach erhalten den Paul Ehrlich- und Ludwig Darmstaedter-Preis 2018. Pressemitteilung vom 23.01.2018","author":"Goethe Universit\u00e4t Frankfurt a.M.","year":"2018","unstructured":"Goethe Universit\u00e4t Frankfurt a.M. (2018) Anthony Cerami und David Wallach erhalten den Paul Ehrlich- und Ludwig Darmstaedter-Preis 2018. Pressemitteilung vom 23.01.2018. \n                    https:\/\/idw-online.de\/de\/news687894\n                    \n                  . Zugegriffen: 21. Feb. 2018"},{"key":"453_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nri802","volume":"2","author":"M Feldmann","year":"2002","unstructured":"Feldmann M (2002) Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2:364\u2013371","journal-title":"Nat Rev Immunol"},{"key":"453_CR4","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1016\/S0140-6736(16)31923-7","volume":"388","author":"TK Kvien","year":"2016","unstructured":"Kvien TK, Uhlig T (2016) EXXELERATE: a\u00a0negative trial with importance for clinical practice. Lancet 388:2781\u20132719","journal-title":"Lancet"},{"key":"453_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","volume":"77","author":"X Mariette","year":"2018","unstructured":"Mariette X, F\u00f6rger F, Abraham B et\u00a0al (2018) Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a\u00a0prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 77:228\u2013233","journal-title":"Ann Rheum Dis"},{"key":"453_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/ncprheum0562","volume":"3","author":"J Dale","year":"2007","unstructured":"Dale J, Alcorn N, Capell H, Madhok R (2007) Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat Clin Pract Rheumatol 3:450\u2013458","journal-title":"Nat Clin Pract Rheumatol"},{"key":"453_CR7","volume-title":"RABBIT \u2013 Rheumatoide Arthritis: Beobachtung der Biologika-Therapie","author":"Deutsches Rheuma-Forschungszentrum (DRFZ)","year":"2018","unstructured":"Deutsches Rheuma-Forschungszentrum (DRFZ) (2018) RABBIT \u2013 Rheumatoide Arthritis: Beobachtung der Biologika-Therapie. \n                    http:\/\/www.biologika-register.de\/home\/\n                    \n                  . Zugegriffen: 21. Jan. 2018"},{"key":"453_CR8","volume-title":"BIKER Register","author":"G Horneff","year":"2018","unstructured":"Horneff G (2018) BIKER Register. \n                    http:\/\/biker-register.de\/\n                    \n                  . Zugegriffen: 21. Jan. 2018"},{"key":"453_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00393-012-1063-z","volume":"72","author":"K Minden","year":"2013","unstructured":"Minden K, Klotsche J, Niwerth M et\u00a0al (2013) Biologikaregister JuMBO. Z\u00a0Rheumatol 72:339\u2013346","journal-title":"Z Rheumatol"},{"key":"453_CR10","volume-title":"EPAR summary for the public \u2013 Enbrel","author":"European Medicines Agency","year":"2014","unstructured":"European Medicines Agency (2014) EPAR summary for the public \u2013 Enbrel. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000262\/WC500027364.pdf\n                    \n                  . Zugegriffen: 21. Jan. 2018"},{"key":"453_CR11","volume-title":"Arzneimittelzulassungen f\u00fcr Kinder","author":"vfa","year":"2018","unstructured":"vfa (2018) Arzneimittelzulassungen f\u00fcr Kinder. \n                    http:\/\/www.vfa.de\/kinder\n                    \n                  . Zugegriffen: 21. Febr. 2018"},{"key":"453_CR12","unstructured":"\u00c4rzte Zeitung Online, Eigenbericht (2011) Vielen Biologika fehlt die Zulassung f\u00fcr Kinder mit Rheuma. \u00c4rzte Zeitung Online 30. Aug. 2011"},{"key":"453_CR13","volume-title":"Warten auf die Zulassung. Frankfurter Rundschau Online. 04.09.2016","author":"P D\u00f6rh\u00f6fer","year":"2016","unstructured":"D\u00f6rh\u00f6fer P (2016) Warten auf die Zulassung. Frankfurter Rundschau Online. 04.09.2016. \n                    http:\/\/www.fr.de\/wissen\/gesundheit\/rheuma-warten-auf-die-zulassung-a-314160\n                    \n                  . Zugegriffen: 21. Jan. 2018"},{"key":"453_CR14","volume-title":"Opinions and decisions on paediatric investigation plans","author":"European Medicines Agency","year":"2018","unstructured":"European Medicines Agency (2018) Opinions and decisions on paediatric investigation plans. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/pip_search.jsp&mid=WC0b01ac058001d129\n                    \n                  . Zugegriffen: 21. Feb. 2018"},{"key":"453_CR15","volume-title":"Kerndokumentation \u2013 Ergebnisse 2014","year":"2018","unstructured":"Gesellschaft f\u00fcr Kinder- und Jugendrheumatologie (Hrsg) (2018) Kerndokumentation \u2013 Ergebnisse 2014. \n                    https:\/\/gkjr.de\/forschungsprojekte\/kerndokumentation\/ergebnisse-2014\/\n                    \n                  . Zugegriffen: 23. Jan. 2018"},{"key":"453_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00393-013-1205-y","volume":"73","author":"W Mau","year":"2014","unstructured":"Mau W, Thiele K, Lamprecht J (2014) Trends der Erwerbst\u00e4tigkeit von Rheumakranken. Z\u00a0Rheumatol 73:11\u201319","journal-title":"Z Rheumatol"},{"key":"453_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3109\/03009742.2014.999351","volume":"44","author":"S Schenck","year":"2015","unstructured":"Schenck S, Niewerth M, Sengler C et\u00a0al (2015) Prevalence of overweight in children and adolescents with juvenile idiopathic arthritis. Scand J Rheumatol 44:288\u2013295","journal-title":"Scand J Rheumatol"},{"key":"453_CR18","volume-title":"K\u00f6rperliche und sportliche Aktivit\u00e4t bei juveniler idiopathischer Arthritis \u2013 Ergebnisse aus dem Sportmodul im Rahmen der Kerndokumentation rheumakranker Kinder und Jugendlicher (Meeting Abstract KR.20)","author":"Milatz f","year":"2016","unstructured":"Milatz f, Niewerth M, Geisemeyer N et\u00a0al (2016) K\u00f6rperliche und sportliche Aktivit\u00e4t bei juveniler idiopathischer Arthritis \u2013 Ergebnisse aus dem Sportmodul im Rahmen der Kerndokumentation rheumakranker Kinder und Jugendlicher (Meeting Abstract KR.20). \n                    http:\/\/www.egms.de\/static\/en\/meetings\/dgrh2016\/16dgrh276.shtml\n                    \n                  . Zugegriffen: 21. Feb. 2018"},{"key":"453_CR19","unstructured":"http:\/\/www.spiegel.de\/gesundheit\/diagnose\/bestandsmarkt-nutzen-etablierter-medikamente-doch-nicht-neu-geprueft-a-943188.html\n                    \n                  . Zugegriffen: 21. Jan. 2018"},{"key":"453_CR20","volume-title":"TK: Rabattpr\u00e4mie f\u00fcr Rheumatologen. apotheke-adhoc.de, 12.03.2016","author":"L Klein","year":"2016","unstructured":"Klein L (2016) TK: Rabattpr\u00e4mie f\u00fcr Rheumatologen. apotheke-adhoc.de, 12.03.2016. \n                    https:\/\/www.apotheke-adhoc.de\/nachrichten\/detail\/politik\/tk-rabattvertrag-acht-kassen-fuer-humira\/?tx_aponews_newsdetail%5B%40widget_4%5D%5BcurrentPage%5D=3&tx_aponews_newsdetail%5B%40widget_4%5D%5BitemsPerPage%5D=1&cHash=52080fe7de06db664df0edcc732aa771\n                    \n                  . Zugegriffen: 21. Jan. 2018"},{"key":"453_CR21","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s00393-016-0071-9","volume":"75","author":"C Gissel","year":"2016","unstructured":"Gissel C, G\u00f6tz G, Repp H (2016) Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany. Z\u00a0Rheumatol 75:1006\u20131015","journal-title":"Z Rheumatol"},{"key":"453_CR22","unstructured":"U.S. National Library of Medicine Clinicaltrials.gov (2017) \n                    http:\/\/www.clinicaltrials.gov\n                    \n                  . Zugegriffen: 21. Jan. 2018"},{"key":"453_CR23","unstructured":"http:\/\/www.fachinfo.de\n                    \n                  . Zugegriffen: 02. M\u00e4rz 2018"},{"key":"453_CR24","unstructured":"http:\/\/www.gelbe-liste.de\n                    \n                  . Zugegriffen: 02. M\u00e4rz 2018"},{"key":"453_CR25","unstructured":"http:\/\/www.vfa.de\/biosimilars\n                    \n                  . Zugegriffen: 02. M\u00e4rz 2018"},{"key":"453_CR26","unstructured":"http:\/\/www.clinicaltrials.gov\n                    \n                  . Zugegriffen: 02. M\u00e4rz 2018"},{"key":"453_CR27","unstructured":"Informa Pharmaprojects. \n                    http:\/\/www.citeline.gov\n                    \n                  . Zugegriffen: 2. M\u00e4rz 2018"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0453-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-018-0453-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0453-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T19:07:59Z","timestamp":1556910479000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-018-0453-2"}},"subtitle":["Fortschritte durch Antirheumatika f\u00fcr Patienten und Gesellschaft"],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["453"],"URL":"https:\/\/doi.org\/10.1007\/s00393-018-0453-2","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"4 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Throm und R.\u00a0H\u00f6mke geben an, dass sie Mitarbeiter des Verbands der forschenden Pharma-Unternehmen (vfa) sind, in dem ebenfalls viele Hersteller der genannten Medikamente Mitglied sind.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}